Combination of RET siRNA and irinotecan inhibited the growth of medullary thyroid carcinoma TT cells and xenografts via apoptosis. (Q39668289)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20704575%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

title

Combination of RET siRNA and irinotecan inhibited the growth of medullary thyroid carcinoma TT cells and xenografts via apoptosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20704575%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20704575%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

author name string

Kimiko Koga

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20704575%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Mihoko Komori

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20704575%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Ryota Narishima

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20704575%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Masahiro Yamasaki

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20704575%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Motoki Hakoshima

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20704575%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Tetsuya Fukui

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20704575%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Yoshie Maitani

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20704575%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

publication date

1 April 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20704575%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20704575%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

volume

101

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20704575%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20704575%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

page(s)

941-947

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20704575%20AND%20SRC:MED&resulttype=core&format=json

The RET proto-oncogene: a molecular therapeutic target in thyroid cancer

9 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01484.X

Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01484.X

Characterization of a multicomponent receptor for GDNF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01484.X

Minireview: RET: normal and abnormal functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01484.X

The development and application of imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01484.X

Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01484.X

A new therapeutic approach in medullary thyroid cancer treatment: inhibition of oncogenic RET signaling by adenoviral vector-mediated expression of a dominant-negative RET mutant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01484.X

Antitumor capacity of a dominant-negative RET proto-oncogene mutant in a medullary thyroid carcinoma model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01484.X

Technology insight: gene therapy and its potential role in the treatment of medullary thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01484.X

Prospects of RNA interference therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01484.X

Genome-wide copy number imbalances identified in familial and sporadic medullary thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01484.X

NaCl induced high cationic hydroxyethylated cholesterol-based nanoparticle-mediated synthetic small interfering RNA transfer into prostate carcinoma PC-3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01484.X

Folate-linked lipid-based nanoparticles for synthetic siRNA delivery in KB tumor xenografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01484.X

The distribution of mRNA expression and protein after hydrodynamic injection of transgene in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01484.X

Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01484.X

Cytotoxic activity of camptothecin and paclitaxel in newly established continuous human medullary thyroid carcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01484.X

Progression of postoperative residual medullary thyroid carcinoma as monitored by plasma calcitonin levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01484.X

RET/PTC1 oncogene signaling in PC Cl 3 thyroid cells requires the small GTP-binding protein Rho.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01484.X

Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01484.X

Regulation of proliferation and apoptosis in sporadic and hereditary medullary thyroid carcinomas and their putative precursor lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01484.X

Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2009.01484.X